TG Therapeutics to Present at the Jefferies 2020 Healthcare Conference
Presentation scheduled for tomorrow, Wednesday, June 3, 2020, at 10:00 AM ET
Get Alerts TGTX Hot Sheet
Join SI Premium – FREE
NEW YORK, June 02, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will participate in a fireside chat during the Jefferies 2020 Healthcare Conference, being held virtually. The fireside chat is scheduled to take place on Wednesday, June 3, 2020 at 10:00 AM ET.
A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company’s website at http://ir.tgtherapeutics.com/events.
ABOUT TG THERAPEUTICS, INC. TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing multiple therapies targeting hematological malignancies and autoimmune diseases. Ublituximab (TG-1101) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing umbralisib (TGR-1202), an oral, once-daily dual inhibitor of PI3K-delta and CK1-epsilon, which may lead to a differentiated safety profile. Both ublituximab and umbralisib, or the combination of which is referred to as "U2", are in Phase 3 clinical development for patients with hematologic malignancies, with ublituximab also in Phase 3 clinical development for Multiple Sclerosis. Additionally, the Company has recently brought into Phase 1 clinical development its anti-PD-L1 monoclonal antibody, cosibelimab (TG-1501), its covalently-bound Bruton’s Tyrosine Kinase (BTK) inhibitor, TG-1701, as well as its anti-CD47/CD19 bispecific antibody, TG-1801. TG Therapeutics is headquartered in New York City. CONTACT:
Jenna BoscoSenior Vice President, Corporate CommunicationsTG Therapeutics, Inc.Telephone: 212.554.4351Email: [email protected]
Source: TG Therapeutics, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BNP PARIBAS GROUP: SUDAN LITIGATION STATEMENT FROM BNP PARIBAS
- Latest Crypto News: Bitcoin Rips Past $77K, Cardano Turns Bullish – Is Apeing Whitelist the Next Move for Traders?
- $120,000 and One Million Visitors in 48 Hours for Solo Founder's Side Project Outbid.lol
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Jefferies & Co, Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share